Based on the results of the analysis of immunological blood parameters, triple therapy using RT+L19–IL2+anti-PD-L1 resulted in a significant increase of PD-1 expression on peripheral CD4+ T cells in the C51 tumor model at day 6 after the start of the triple therapy, while this expression decreased in the CT26 tumor model and remained unchanged in the LLC model (figure 3A). Here, CD274 is linked to neoplasm.